We are currently experiencing intermittent difficulty during Premium user registration. We appreciate your patience as we investigate.

The Cheapest Stock in the World

With very high uncertainty comes our highest potential on I-Mab stock.

Andrew Willis 23 December, 2022 | 4:48AM
Facebook Twitter LinkedIn

 

 

Explore more Stock of the Week episodes here

Andrew Willis: Investors were very generous and risk-seeking up until late last year when we saw speculative investments take the brunt of a broad equity decline, as they often do. This was around the same time that rumours were brewing about Chinese biopharma stock, I-Mab (IMAB).

Reports were coming in about talks with large U.S. and European drugmakers on partnering or investing in I-Mab and its research around cancer and blood conditions. Senior equity analyst Jay Lee says the company is quite innovative and has the potential to create first-in-class and best-in-class drugs.

I-Mab announced partnerships since the gossip, like one with Roche (RHHBY) in November, but in the months that followed, its stock suffered as increasingly impatient equity investors collided with the long-term nature of the drug business. With timelines like 2024 for the potential approval of key assets, and 2025 for the possibility of generating significant, the market may have adverse reactions to Morningstar’s cheapest stock – and it could take a while to kick in.

For Morningstar, I’m Andrew Willis.

Get the Latest Stock Insights in Your Inbox

Subscribe Here

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar Rating
I-MAB ADR6.80 USD0.00Rating

About Author

Andrew Willis

Andrew Willis  is Senior Editor at Morningstar.ca. He previously produced content for Fidelity Investments and finance industry events for Euromoney Institutional Investor and has written in the past for Thomson Reuters and CNN. Follow him on Twitter @Andrew_M_Willis.

© Copyright 2023 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy